Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247377 | 0.88 | SYK (0.37) | BACE1KCNH2SYKATRMETAP1 | |
| SCHEMBL3244253 | 0.87 | BACE1 (0.40) | BACE1KCNH2SYKMALT1SMARCA2 | |
| SCHEMBL3359222 | 0.85 | SYK (0.38) | SYKATRMETAP1 | |
| SCHEMBL3239035 | 0.77 | BACE1 (0.52) | BACE1KCNH2SYK | |
| SCHEMBL3248775 | 0.75 | SCN9A (0.33) | SYKRXFP1 | |
| SCHEMBL3357372 | 0.74 | TDP2 (0.35) | — | |
| SCHEMBL3242312 | 0.72 | BACE1 (0.33) | BACE1KCNH2 | |
| SCHEMBL3249126 | 0.68 | BACE1 (0.50) | BACE1KCNH2SYK | |
| SCHEMBL21614653 | 0.67 | SMARCA2 (0.60) | RORCRXFP1MALT1ATRSMARCA2 | |
| SCHEMBL3357632 | 0.66 | BACE1 (0.52) | BACE1KCNH2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | BACE1 3/4885KCNH2 4652/4885SYK 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.